Study 301

Study 301 is a pivotal clinical trial evaluating the efficacy and safety of the Alzheimer’s disease drug Leqembi (lecanemab) in patients with early-stage disease.

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.